Supplementary Material

Preferences for COVID-19 vaccination in people with chronic immune-mediated inflammatory diseases

Authors: Glen S. Hazlewood, Ines Colmegna, Carol Hitchon, Paul R Fortin, Sasha Bernatsky, Ann E Clarke, Dianne Mosher, Todd Wilson, Megan Thomas, Claire Barber, Mark Harrison, Nick Bansback, Laurie Proulx, Dawn P Richards, Gilaad G. Kaplan

Contents:

- Pg 2. Supplementary Table S1. Characteristics of Medications Held
- Pg 3. Supplementary Table S2. Perceived concerns of COVID-19 infection and concerns and benefits of vaccination
- Pg 4. Supplementary Table S3. Results of internal validity testing
- Pg 5. Supplementary Table S4. Association between patient characteristics and group membership in the latent class analysis
- Pg 7. Supplementary Text S1. Full DCE Survey

Supplementary Table S1. Characteristics of Medications Held

Medication	No	Yes, held before vaccine	Yes, held after vaccine	Yes, held before and after vaccine
Any medication	451 (82%)	22 (4%)	50 (9%)	71 (13%)
Anti-TNF inhibitors	125 (80.1)	4 (2.6)	13 (8.3)	14 (9)
Rituximab	4 (50)	1 (12.5)	0 (0)	3 (37.5)
Vedolizumab	29 (100)	0 (0)	0 (0)	0 (0)
Other biologic DMARDS	49 (81.7)	0 (0)	5 (8.3)	6 (10)
JAK Inhibitors	15 (65.2)	0 (0)	4 (17.4)	4 (17.4)
Methotrexate	58 (42)	8 (5.8)	25 (18.1)	47 (34.1)
Azathioprine (Imuran) or 6-mercaptopurine	53 (94.6)	2 (3.6)	1 (1.8)	0 (0)
Hydroxychloroquine (Plaquenil)	135 (94.4)	3 (2.1)	2 (1.4)	3 (2.1)
Leflunomide (Arava)	17 (100)	0 (0)	0 (0)	0 (0)
Sulfasalazine	34 (85)	0 (0)	2 (5)	4 (10)
Mycophenolate mofetil (CellCept)	20 (95.2)	0 (0)	1 (4.8)	0 (0)
Calcineurin inhibitors	6 (100)	0 (0)	0 (0)	0 (0)
Prednisone (20mg per day or less)	26 (83.9)	1 (3.2)	0 (0)	4 (12.9)
Prednisone (more than 20mg per day)	2 (100)	0 (0)	0 (0)	0 (0)
Other	46 (83.6)	3 (5.5)	3 (5.5)	3 (5.5)
None	29 (93.5)	1 (3.2)	0 (0)	1 (3.2)

Supplementary Table S2. Perceived concerns of COVID-19 infection and concerns and benefits of vaccination

Biggest concern about Covid-19 (scale 0 to 10), median (25 ^{th,} 75 th percentiles)	
Dying due to COVID-19 disease	6 (3, 9)
Ending up in hospital due to COVID-19 disease	8 (5, 10)
Chronic long-term COVID-19 symptoms that interfere with your quality of life and/or ability to work	8 (5, 10)
Passing COVID-19 on to family and friends	9 (6, 10)
Passing COVID-19 on to members of your community	8 (5, 10)
Impact of COVID-19 on society and the economy	8 (5, 10)
mportant benefits of Covid-19 vaccine, n (%)	
Protect myself from getting COVID-19	533 (96.7)
Protect family and friends from getting COVID-19	531 (96.4)
Protect others in my community from getting COVID-19	494 (89.7)
Protect myself from needing to go to hospital or dying from COVID-19	524 (95.1)
Get my life back to normal	436 (79.1)
Greater freedom of movement (able to leave home or travel)	469 (85.1)
Peace of mind	474 (86.0)
Return society to normal	435 (78.9)
Other	21 (3.8)
Potential concerns about the Covid-19 vaccine, n (%)	
Known/Reported side effects	245 (44.5)
Allergic reaction	127 (23.1)
New/Unknown side effects	274 (49.7)
Uncertainty about how well it works	231 (41.9)
General distrust in all vaccines	14 (2.5)
General distrust in COVID-19 vaccines	33 (6.0)
May not be effective for me	266 (48.3)
May cause my autoimmune condition to get worse	257 (46.6)
Developed too quickly, without enough testing	100 (18.1)
Unnecessary for me (I don't feel my risk of getting COVID-19 is very high)	7 (1.3)
Other	22 (4.0)

Supplementary Table S3. Results of internal validity testing

Test Type	DCE Study No. of Failures / No. of Tests (%)	Published DCE % Failures [1] (Mean (SD))
Straight-lining	15 / 551 (3%)	7 (11)
Within-set dominated pairs	3 / 187 (0.5%)	18 (20)
Across-set dominated pairs	23 / 12,484 (0.2%)	6 (9)

Summary of results:

<u>Straight-lining</u>: Participants choosing the same option (A or B) in every choice or nearly every choice. Of the 551 respondents, three respondents (0.5%) chose the same alternative (A or B) in every choice, three chose the same alternative in 9 of 10 tasks, and nine respondents (1.6%) chose the same alternative in 8 of 10 tasks.

<u>Within-set dominated pairs</u>*: Participants choosing an option that was objectively worse for all attributes. Of the 187 times a clearly dominated alternative was present in a choice task, the dominated alternative was selected three times (0.5%).

<u>Across-set dominated pairs</u>*: Where a choice option is presented in two questions and patients choose this option in one question and an inferior choice in the second question. Of the 12,484 tests, the dominated alternative was chosen 23 times. In all 23 cases (17 participants failed one test and three participants failed two tests), participants chose a vaccination option in one choice-task and chose the none option in a subsequent choice, even though there was a better vaccination option than the previous choice task.

*In the dominated alternative tests, we assumed vaccine effectiveness, flare and rare but serious risks had an unambiguous preference ordering (e.g. more effective and safer vaccines being preferred). We did not assume a preference for number of doses. Therefore, we only conducted these tests for choices where the number of doses was the same for both vaccine options.

Supplementary Table S4. Association between patient characteristics and group membership in the latent class analysis

			Univariate associations		Multivariable associations	
Patient Characteristics	Risk averse group* (N = 111)	Risk tolerant group** (N = 440)	Odds ratio (95% CI)	P-value	Odds ratio (95% CI)	P-value
Age, mean (SD)	48 (16)	46 (14)	1.01 (0.99, 1.02)	0.332	0.99 (0.97, 1.01)	0.164
Female gender, n (%)	93 (83.8)	395 (89.8)	0.59 (0.33, 1.06)	0.079	0.47 (0.24, 0.91)	0.025
Caucasian ethnicity, n (%)	91 (82.0)	397 (90.2)	0.49(0.28, 0.88)	0.016	0.68 (0.34, 1.39)	0.292
Education university degree or above, n (%)	59 (53.2)	231 (52.5))	1.01 (0.66, 1.53)	0.975		
Annual household income >100,000, n (%)	31 (27.9)	192 (43.6)	0.50(0.32, 0.79)	0.003	0.46 (0.28, 0.76)	0.003
Employment status working, n (%) Immune Mediated Inflammatory Disease, n (%)	75 (67.6)	282 (64.1)	1.17 (0.75, 1.82)	0.493		
Inflammatory arthritis	47 (42.3)	198 (45.0)	0.90 (0.59, 1.37)	0.615		
Inflammatory bowel disease (IBD) – (Crohn's Disease / Ulcerative Colitis)	40 (38.5)	213 (48.4)	0.68 (0.44, 1.04)	0.076	1.08 (0.57, 2.06)	0.814
Systemic lupus erythematosus (SLE) Medications, n (%)	22 (19.8)	66 (15.0)	1.40 (0.82, 2.39)	0.217		
TNF inhibitors, JAK inhibitors, Other biologic DMARDS	52 (46.8)	236 (53.6)	0.76 (0.50, 1.16)	0.201		
Rituximab / Mycophenolate mofetil (CellCept)*	10 (9.0)	20 (4.5)	2.08 (0.94, 4.58)	0.069	1.95 (0.72, 5.32)	0.191
Patient global assessment of disease activity (scale 0 to 10), median (25 th , 75 th percentile)	3 (1, 6)	2 (2, 6)	0.97 (0.89, 1.05)	0.413		
Flares requiring a change in treatment in the past year, median (25 th , 75 th)	1 (0, 3)	1 (0, 3)	1.01 (0.99, 1.03)	0.424		
Number of comorbidities, median (25th, 75th)	0(0,1)	0(0,1)	1.10 (0.84, 1.43)	0.499		
Current smoker, n (%)	6 (5.4)	19 (4.3)	1.27 (0.49, 3.25)	0.624		
Covid-19 vaccinated, n (%)	107 (96.4)	412 (93.6)	1.82 (0.62, 5.29)	0.273		
Covid Vaccine Concerns, n (%)	. ,	. ,	. , ,			
May cause my autoimmune condition to get worse	58 (52.5)	199 (45.2)	1.33 (0.87, 2.01)	0.186		
New / unknown side effects	58 (52.5)	216 (49.1)	1.13 (0.75, 1.72)	0.552		
Known / reported side effects	52 (46.9)	193 (43.9)	1.13 (0.74, 1.71)	0.217		
Recruited through a clinical cohort	41 (36.9)	101 (23.0)	1.97 (1.26, 3.07)	0.003	1.67 (0.85, 3.28)	0.138
stant along #1 in Figure 2	(200)	(-2.0)	=== (===0,0.07)		1101 (1100, 0120)	

^{*}Latent class #1 in Figure 2
**Latent classes #2 and #3 in Figure 2 combined

References


1. Johnson FR, Yang JC, Reed SD. The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments. Value Health. 2019 Feb; 22(2):157-160.

What is this survey about?

As you know, there are now several effective, approved vaccines that could make a big difference in global efforts to help control the COVID-19 pandemic.

However, we know that some people have concerns about taking the vaccine, including those living with autoimmune conditions.

The purpose of this survey is to share what we know about COVID-19 vaccines so far, and to understand **your preferences around having (or not having) a vaccine**, when it is available to you.



About you

Which of the following autoimmune conditions do you have (check all that apply)?
Ankylosing spondylitis / spondyloarthritis
Behcet's disease
☐ Inflammatory bowel disease (IBD) - Crohn's Disease
☐ Inflammatory bowel disease (IBD) - Ulcerative Colitis
Juvenile idiopathic arthritis (JIA)
Myositis
Multiple sclerosis (MS)
Polymyalgia rheumatica (PMR)
Psoriasis
Psoriatic arthritis
Reactive arthritis
Rheumatoid arthritis (RA)
Scleroderma
Sjogren's syndrome
Systemic lupus erythematosus (SLE)
Vasculitis
Other
None

Back Next

100%

100%

Please indicate if	vour diagnosis	(or diagnoses) has been confirmed b	v a specialist (select and	v/all that apply)

Ankylosing spondylitis / spondyloarthritis
Behcet's disease
Inflammatory bowel disease (IBD) - Crohn's Disease
Inflammatory bowel disease (IBD) - Ulcerative Colitis
Juvenile idiopathic arthritis (JIA)
Myositis
Multiple sclerosis (MS)
Polymyalgia rheumatica (PMR)
Psoriasis
Psoriatic arthritis
Reactive arthritis
Rheumatoid arthritis (RA)
Scleroderma
Sjogren's syndrome
Systemic lupus erythematosus (SLE)
Vasculitis
Other
None
Back Next

Your medications

Which medications are you currently taking for your autoimmune condition/s?
Abatacept (Orencia)
Adalimumab (Humira, Hadlima, Hyrimoz, Idacio, Hulio, Amgevita)
Anakinra (Kineret)
Azathioprine (Imuran) or 6-mercaptopurine
Baricitinib (Olumiant)
Belimumab (Benlysta)
Budesonide (Entocort)
Canakinumab (Ilaris)
Certolizumab (Cimzia)
Chloroquine (Aralen)
Cyclophosphamide
Cyclosporine
Etanercept (Enbrel, Brenzys, Erelzi)
Golimumab (Simponi)
Hydroxychloroquine (Plaquenil)
Infliximab (Remicade, Inflectra, Renflexis, Remsima, Avsola)
☐ Ixekizumab (Taltz)
Leflunomide (Arava)
Mesalamine (Asacol, Pentasa, Salofalk, Mezavant)
Methotrexate
Mycophenolate mofetil (CellCept)
Prednisone (20mg per day or less)
Prednisone (more than 20mg per day)
Rituximab (Rituxan, Riximyo, Ruxience)
Secukinumab (Cosentyx)
Sulfasalazine
Tacrolimus
Cocilizumab (Actemra)
Tofacitinib (Xeljanz)
Upadacitinib (Rinvoq)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)
Other
None

Back

Next

How do the COVID-19 vaccines work?

All vaccines work by training your immune system to respond to an infection. They do this in different ways. Some, including the flu shot and COVID-19 vaccines in development, use a small, dead piece of the virus called a protein.

Other vaccines, such as those currently approved for COVID-19, give your cells instructions on how to make this protein. Your immune system learns to recognize this protein. If you become infected with the virus, your body gets rid of the infection so you do not become sick.

These vaccines do not contain live virus, so there is no chance of getting COVID-19 from them.

More detailed and up-to-date information on the COVID-19 vaccines available can be found on the Government of Canada website (https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines.html).



What are the benefits of the COVID-19 vaccine?

These are some of the most important benefits of the COVID-19 vaccine:

Preventing COVID-19 infection

These vaccines prevent ~60% to 95% of COVID-19 infections in people who get the vaccines. This is even better than the annual flu vaccine, which prevents the flu around 40% to 60% of the time.

Reducing severity of COVID-19

COVID-19 is less severe in people who get the vaccine.

Protecting others

Getting vaccinated yourself may also protect people around you. As more people get vaccinated, we will see less COVID-19 spread.



What about side effects or risks?

Like all vaccines, there are some possible temporary side effects or risks with the COVID-19 vaccine:

- sore arm where the injection was given
- temporarily swollen lymph nodes
- tiredness
- fever, chills
- headache
- general muscle or joint pain

Side effects vary from person to person. They usually wear off within a day or so, but some people can have reactions that last several days and could cause them to miss school, work or family activities.

There is a risk of allergic reactions in those people with allergies to a part of the COVID-19 vaccine, which can be severe. For this reason, you must remain under observation where you get the vaccine for at least 15 minutes after the vaccination (this is also true for other types of vaccinations).

Other rare but serious side effects may also be identified; for example, recent reports of blood clots with some COVID-19 vaccines.



What you need to know if you have an autoimmune condition

Is the vaccine still safe and effective?

We don't yet know about the side effects or how well COVID-19 vaccines work in people with autoimmune conditions. People with these conditions were mostly excluded from COVID-19 vaccine trials.

We do know that other vaccines (e.g. flu vaccines) provide good protection for most people with autoimmune conditions, with side effects similar to the general population. Other vaccines do not usually trigger flares of autoimmune conditions. We'll continue to learn more about this as more people receive the COVID-19 vaccine.

These vaccines do not contain live COVID-19 virus, so there is no chance of getting COVID-19 from them.



Great!


We will now ask some questions to understand your thoughts, concerns and preferences around the COVID-19 vaccine.

Please remember there are no right or wrong answers. We are interested in your preferences.



Your biggest concerns about COVID-19

How concerned are you about each of these (on a scale of 0-10)?





Benefits of the COVID-19 vaccine

Below are some potential benefits of having the COVID-19 vaccine.

Please select any/all that are important to you.
Protect myself from getting COVID-19
Protect family and friends from getting COVID-19
Protect others in my community from getting COVID-19
Protect myself from needing to go to hospital or dying from COVID-19
Get my life back to normal
Greater freedom of movement (able to leave home or travel)
Peace of mind
Return society to normal
Other
Back Next
0%

Concerns about the COVID-19 vaccine

Below are some potential concerns people may have about having the COVID-19 vaccine.

already had it).
☐ Known/Reported side effects
Allergic reaction
New/Unknown side effects
Uncertainty about how well it works
General distrust in all vaccines
General distrust in COVID-19 vaccines
May not be effective for me
May cause my autoimmune condition to get worse
Developed too quickly, without enough testing
Unnecessary for me (I don't feel my risk of getting COVID-19 is very high)
Other
Back Next
0%

Some questions about you and the COVID-19 vaccine

Have you been tested fo	r COVID-19?			
◯ Yes				
○ No				
O Prefer not to say				
		Back	Next	
	00/			1000/

YesNo○ Prefer not to say

Have you already had a COVID-19 vaccine?

 $\bigcirc \text{ Yes}$

○ No

If given a choice, which of these COVID-19 vaccines would you have (select all that apply)?

AstraZeneca-Oxford
Johnson & Johnson
Moderna
Pfizer-BioNTech
None of the above
I'm not sure

Which COVID-19 vaccine did you have?

AstraZeneca-Oxford				
O Johnson & Johnson				
Moderna				
Pfizer-BioNTech				
Other				
Unsure				

How many doses have you had?

 \bigcirc

 \bigcirc 2

D - f		your COVID-19			/	/	-4/-1	1 414	
Retore	voli nan i	VALIF (.(.)VII)=19	vaccine did	voli nave a	nreterence i	INIBASE SEIR	ct anv/ai	ıtnat	annivi
DCIOIC 1	y ou muu	your ootib-io	vaccinc, aid	you nave a	profesorous (picase seic	ot ally/al	·	uppiy,.

AstraZeneca-Oxford				
Johnson & Johnson				
Moderna				
Pfizer-BioNTech				
I had no preference				
		Back	Next	
	0%			100%

Did you interrupt or hold any of your autoimmune medications around the time you had the COVID-19 vaccine?

	No	Yes, held before vaccine	Yes, held after vaccine	Yes, held before and after vaccine
Abatacept (Orencia)	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Adalimumab (Humira, Hadlima, Hyrimoz, Idacio, Hulio, Amgevita)	0		0	0
Anakinra (Kineret)	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Azathioprine (Imuran) or 6-mercaptopurine	\bigcirc	\circ	\circ	0
Baricitinib (Olumiant)	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Belimumab (Benlysta)	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Budesonide (Entocort)	\bigcirc	0		\bigcirc
Canakinumab (Ilaris)	0	0	0	0
Certolizumab (Cimzia)	0	0	0	0
Chloroquine (Aralen)	0	0	O	0
Cyclophosphamide	0	0	O	0
Cyclosporine	\bigcirc	O	O	O
Etanercept (Enbrel, Brenzys, Erelzi)	0	<u> </u>	0	0
Golimumab (Simponi)	\circ	0	O	0
Hydroxychloroquine (Plaquenil)	\bigcirc	\circ	\circ	0
Infliximab (Remicade, Inflectra, Renflexis, Remsima, Avsola)	0	0	0	0
Ixekizumab (Taltz)				
Leflunomide (Arava)	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Mesalamine (Asacol, Pentasa, Salofalk, Mezavant)	\bigcirc	0	\bigcirc	0
Methotrexate		\bigcirc		\bigcirc
Mycophenolate mofetil (CellCept)	\bigcirc	\bigcirc	\bigcirc	
Prednisone (20mg per day or less)	\bigcirc	\circ	0	0
Prednisone (more than 20mg per day)	\bigcirc	\circ	0	0
Rituximab (Rituxan, Riximyo, Ruxience)	\circ	0	0	0
Secukinumab (Cosentyx)	\bigcirc	\circ	0	0
Sulfasalazine	O	O	O	O
Tacrolimus	\bigcirc	O	\bigcirc	O
Tocilizumab (Actemra)		O	O	O
Tofacitinib (Xeljanz)	\bigcirc	O	0	0
Upadacitinib (Rinvoq)				
Ustekinumab (Stelara)		O		
Vedolizumab (Entyvio)		U		U
Other	\bigcirc		\bigcirc	\bigcirc

Supplementary Material

The Journal of Rheumatology is not responsible or liable for the content of the supplementary material, which has been supplied by the author(s).

J Rheumatol

Back Next

0% 100%


Introduction to choice questions

On the next few pages, we will show you 2 different COVID-19 vaccine options, and ask you to **pick the ONE that you prefer.**

There are no wrong answers... we are interested in **YOUR preferences**.

The vaccine options will not necessarily reflect real COVID-19 vaccines that are available. However, we ask that you read each option, and answer as if they were real options that were available to you now.


We will start with a "warm-up" question for you to get used to the choice questions style.



Warm-up example

If these 2 COVID-19 vaccine options were presented to you now, which would you choose?

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet.



Great!




The warm-up question had just two considerations (number of shots and vaccine effectiveness). In the full choice questions, there will be four.

These are:

- Number of shots
- Vaccine effectiveness after full dose (preventing symptomatic COVID-19 infection)
- · Likelihood of having a flare of your autoimmune condition in the month after having the vaccine
- Rare but serious risks (in addition to the small chance of allergic reaction)

We will explain these over the next 4 pages.




Consideration 1 of 4

Number of shots

Survey options:

- One shot
- Two shots (separated by 1 month, as tested in the trials)
- Two shots (separated by 4 months, longer than tested in the trials)

COVID-19 vaccines require one or two injections (shots). Full protection is typically achieved 2 weeks after the last dose. For vaccines that require 2 shots, the first shot still provides some (but not full) protection.



Consideration 2 of 4


Vaccine effectiveness after full dose (preventing symptomatic COVID-19 infection)

Survey options:

• Ranging from 30% to 95%

This is the how well the vaccine works to prevent COVID-19 infection. A vaccine that is 70% effective means it prevents infection in 70 out of 100 people after the full vaccine dose (up to 2 shots). By 'symptomatic' we mean symptoms such as fever, shortness of breath or cough. If you develop symptomatic COVID-19, the chance of you being hospitalized or dying will vary by your age and other risk factors.

In this survey, please interpret the percentage shown as if it applies <u>specifically for you</u>. Assume that it factors in any impact your medications may have on the effectiveness of the vaccine.



Consideration 3 of 4


Likelihood of having a flare of your autoimmune condition in the month after having the vaccine.

Survey options:

• Ranging from Less than 1% to 20%

By 'flare' we mean an increase in disease activity that is serious enough for you to contact your physician or healthcare team, and requires medication to treat. In many cases, this will just mean short-term medication, although some patients might need more major changes to their treatment.

It is important to note that we DO NOT think that vaccines cause flares of disease. However, in this survey, we are interested in understanding how important this is to you, given the benefits of vaccines.



Consideration 4 of 4

Rare but serious risks

Survey options:

- · None identified
- 1 out of 1,000,000
- 5 out of 1,000,000
- 10 out of 1,000,000


With any vaccine, there is a small chance of a serious allergic reaction, called anaphylaxis. It usually happens within 15 minutes after a person receives the vaccine and is treatable.

Occasionally, other rare but serious side effects are also identified. An example is the blood clots identified with some COVID-19 vaccines. These can be fatal, but can also be treated if recognized quickly.

It is helpful to compare the likelihood of these risks with those from COVID-19 itself. For example, an average 45 year-old in Canada with COVID-19 has a 6% risk* of hospitalization. This means that 60,000 out of 1,000,000 45 year-olds with COVID-19 would be hospitalized. This compares to between 1 and 10 people (out of 1,000,000) having a rare but serious side effect from the vaccine.

For this survey, we ask you to consider potential rare but serious side effects that are <u>in addition</u> to the small chance of an allergic reaction possible with all the vaccines.

*Source: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html#a7



Let's begin!

We're now ready to start with the choice questions (there are 10 in total).

Vaccine 2

Select

None

Select

If these were your COVID-19 vaccine options, which one would you choose?

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (1 of 10)

Vaccine 1

Select

Back

0%

Vaccine effectiveness after full 50% 30% I would not have dose (preventing symptomatic either of these **COVID-19**) vaccines Likelihood your autoimmune 10% Less than 1% condition will flare in the month after having the vaccine Rare but serious risks None identified 1 out of 1,000,000 **Number of shots** Two shots 1 shot (as tested in (separated by 4 the trials) months, longer than tested in the trials)

100%

Next

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (2 of 10)


Vaccine effectiveness after full dose (preventing symptomatic COVID-19)

Likelihood your autoimmune condition will flare in the month after having the vaccine

Rare but serious risks

Number of shots

0%



100%

Back Next

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (3 of 10)

Vaccine effectiveness after full dose (preventing symptomatic COVID-19)

Likelihood your autoimmune condition will flare in the month after having the vaccine

Rare but serious risks

Number of shots

0%

Vaccine 1 Vaccine 2 75% 95% 2% 20% 10 out of 1,000,000 5 out of 1,000,000 Two shots 1 shot (as tested in (separated by 1 the trials) month, as tested in the trials) Select Select



Back

Next

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (4 of 10)

Vaccine 1 Vaccine 2 None Vaccine effectiveness after full 50% 30% I would not have dose (preventing symptomatic either of these **COVID-19**) vaccines Likelihood your autoimmune 2% Less than 1% condition will flare in the month after having the vaccine Rare but serious risks None identified 1 out of 1,000,000 **Number of shots** 1 shot (as tested in Two shots the trials) (separated by 1 month, as tested in the trials) Select Select Select

Back

0%

Next

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (5 of 10)


Vaccine effectiveness after full dose (preventing symptomatic COVID-19)

Likelihood your autoimmune condition will flare in the month after having the vaccine

Rare but serious risks

Number of shots

0%



Back

Next

None

vaccines

Select


If these were your COVID-19 vaccine options, which one would you choose?

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (6 of 10)

Vaccine effectiveness after full 30% dose (preventing symptomatic **COVID-19**) Likelihood your autoimmune 5% condition will flare in the month after having the vaccine

Rare but serious risks

Number of shots



Next Back

0% 100%


Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (7 of 10)

Vaccine effectiveness after full dose (preventing symptomatic COVID-19)

Likelihood your autoimmune condition will flare in the month after having the vaccine

Rare but serious risks

Number of shots



Back Next


Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (8 of 10)

Vaccine effectiveness after full dose (preventing symptomatic COVID-19)

Likelihood your autoimmune condition will flare in the month after having the vaccine

Rare but serious risks

Number of shots



Back Next

0% 100%

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (9 of 10)

Vaccine effectiveness after full dose (preventing symptomatic COVID-19)

Likelihood your autoimmune condition will flare in the month after having the vaccine

Rare but serious risks

Number of shots

0%

Vaccine 1 Vaccine 2 50% 95% Less than 1% 2% 5 out of 1,000,000 10 out of 1,000,000 1 shot (as tested in Two shots the trials) (separated by 4 months, longer than tested in the trials) Select Select

None

I would not have either of these vaccines

Back

Next

Important: If you have already had a COVID-19 vaccine, please respond as though you haven't yet. (10 of 10)

Vaccine effectiveness after full dose (preventing symptomatic COVID-19)

Likelihood your autoimmune condition will flare in the month after having the vaccine

Rare but serious risks

Number of shots

Vaccine 1 Vaccine 2 95% 30% 2% 20% None identified None identified Two shots Two shots (separated by 1 (separated by 1 month, as tested in month, as tested in the trials) the trials) Select Select

None

I would not have either of these vaccines

Back

Next

Final questions

Some postsecondary

These help us to understand your potential COVID-19 risk.

What is y	our age?													
What is y	our gender i	dentit	y?											
◯ Male														
Fem	ale													
O Non-	binary / third	gendei	r											
O Prefe	er not to answ	er er												
Othe	r													
What is y	our ethnic o	rigin (select	all tha	at appl	y)?								
Asia	n													
Blac														
	casian													
	Nations													
Hisp														
	h Asian													
Othe	r													
	•													
Prefe	er not to answ	er												
Considering how you are		s in wh	nich ill	ness	and he	ealth c	onditio	ons m	ay affe	ct you	u at th	is time	e, please indicate	below
		0	1	2	3	4	5	6	7	8	9	10		
	Very well												Very poorly	
In the past y	ear, approxi	matel	y how	many	flares	of yo	ur aut	oimmı	ine co	nditio	n have	e you l	nad?	
and requires		treat.	In mar										sician or healthcar some patients mig	
Select hiç	ghest level re	eceive	ed:											
○ Elem	entary schoo	I												
() High	school													

Postsecondary certificate or diplo	ma
Ouniversity bachelor's degree	
Above university bachelor's degre	ee
Other	
O Prefer not to answer	
What is your annual household inco	ome?
>\$20,000	
\$20,000-\$49,999	
\$50,000-\$99,999	
\$100,000-\$249,000	
>\$250,000	
O Prefer not to answer	
Do you currently work inside or outs COVID-19)?	side your home (this is to better understand your possible exposure to
Inside my home	
Outside my home	
I am not currently working	
Prefer not to answer	
Which province do you live in?	
Alberta	
British Columbia	
Manitoba Nava Brancowiele	
New Brunswick Newfoundland and Labrador	
Northwest Territories	
Nova Scotia	
Nunavut	
Ontario	
Prince Edward Island	
Quebec	
○ Saskatchewan	
Yukon	
Not applicable (I live outside Cana	ada)
Prefer not to answer	,
What are the first 3 digits of your po	
_	f COVID-19 in the community you live in.
O Postcode	
Not applicable (I live outside Cana	ada)

The following conditions have been listed by the Government of Canada as risk factors for more severe outcomes (see Canada.ca/coronavirus).
Please indicate if you have any of the following chronic conditions (select any/all that apply):
Lung Disease
Heart Disease
High Blood Pressure (Hypertension)
Diabetes
☐ Kidney Disease
Liver Disease
☐ Dementia
Stroke
Cancer
Do you smoke (cigarettes)?
○ Yes
○ No (never)
○ No (but have in the past)
O Prefer not to answer
Back Next
0%

Prefer not to answer

Summary and invitation to future research

Thank you for all your responses.

We are hoping to conduct additional studies to better understand the benefits and safety of COVID-19 vaccines in people with autoimmune conditions. If you would like to receive an e-mail about these studies, when available, please provide your email address below. Your email address will not be shared outside of our research team.

By opting in, you are under no obligation to participate in any of the studies you receive information about, and you can request to opt out of receiving our research emails at any time. Thank you.

(Optional) Please enter your email address here:									
Any other comments:									
Thank you again for your participation.									
Please click Next to submit the survey.									
	Back	Next							
0%			100%						